Pharma
Has deep visibility into internal portfolios, but limited visibility across other companies’ private failures.
FAILED DRUG PROGRAMS, REBUILT
We turn problematic science
into new medicines.
kcat acquires or licenses overlooked drug programs, compares related failures, diagnoses what actually broke, and rebuilds the strongest therapeutic paths.
Better. Cheaper. Faster.
BIOLOGY. COMPUTATION. INTELLIGENCE.
SCROLL TO DISCOVER
01 — THE PROBLEM
Nine out of ten drugs fail, and the evidence goes in a drawer.
Every dead program leaves behind tox findings, PK across species, formulation failures and often full clinical datasets. Much of it never becomes public. Pharma can mine its own failures; what no company can do is compare its failures with everyone else’s.
~90%of clinical drug candidates fail to reach approval
Large shareof development evidence never becomes readily accessible in the public record
WHY THIS REQUIRES A DIFFERENT MODEL
AI drug discovery
Can combine public and proprietary discovery data, but is rarely built around cross-company failed-program evidence.
Asset buyers
Operate around transactions and ownership; kcat is built around comparative scientific reconstruction.
The value sits in comparing failures across companies.
That is where kcat starts.
That is where kcat starts.
02 — WHAT WE DO
One failure is an anecdote.
Eight is evidence.
One dead program gives you n=1 with every cause mixed together. Put related failed datasets behind the same question and you can see whether the real problem was the target, the molecule, the patients, or the way the study was run.
FAILED PROGRAM A
FAILED PROGRAM B
FAILED PROGRAM C
FAILED PROGRAM D
FAILED PROGRAM E
KCAT CLUSTER
Break the failure apart
- Target
- Molecule
- Patients
- Study design
ONE ANSWERNEW
PATH
PATH
Aggregate
Identify, license or acquire relevant programs early.
Cluster
Bring 5 to 10 related programs behind one target or biological question.
Analyze
Break the failure apart and test which explanation survives the evidence.
Advance
The evidence determines the next path.
03 — THE MODEL
We secure the rights to rebuild, and let the evidence determine the next path.
The objective is not to force a predetermined transaction structure. kcat reconstructs the program, generates new evidence and advances the strongest path with the right development partner or vehicle.
01SECURE
Development rights + data + right of reference
02REBUILD
Related failures + new formulation, route, dose or patients + new IP
When the evidence supports it, the rebuilt program can move forward with a development partner that brings the right capabilities and execution path.
For selected programs, kcat can continue building the evidence through a dedicated development structure before the next strategic decision.
A DIFFERENT DATA ADVANTAGE